First Tracks Biotherapeutics, Inc. (TRAX) stock
TRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026
$43.57−2.99 (-6.42%)
Close on Nov 17, 2026Market cap $1.56BP/E –Yield –
First Tracks Biotherapeutics cash
Cash and short-term investments held at the end of each period.
First Tracks Biotherapeutics's cash was $155.63M at Sep 30, 2026. For fiscal 2025 it was $311.64M, up 153.2% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $311.64M | +153.2% |
| FY2024 | Dec 31, 2024 | $123.08M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $155.63M | +41.7% |
| Q2 FY2026 | Jun 30, 2026 | $168.02M | +279.3% |
| Q1 FY2026 | Mar 31, 2026 | $286.46M | +190.4% |
| Q4 FY2025 | Dec 31, 2025 | $311.64M | +153.2% |
| Q3 FY2025 | Sep 30, 2025 | $109.83M | – |
| Q2 FY2025 | Jun 30, 2025 | $44.30M | – |
| Q1 FY2025 | Mar 31, 2025 | $98.64M | – |
| Q4 FY2024 | Dec 31, 2024 | $123.08M | – |
See a number that looks wrong?